| Schedule of Basic and Diluted, Loss Per Share |
A reconciliation of net income available to common stockholders and the number of shares in the calculation of basic and diluted earnings per share was calculated as follows: | | | | | | | | | | | | | | | | | | | | | | | | | For the Three Months Ended June 30, | | For the Six Months Ended June 30, | | (in thousands, except for share and per share amounts) | 2024 | | 2023 | | 2024 | | 2023 | Net income attributable to Privia Health Group, Inc. common stockholders | $ | 3,467 | | | $ | 7,274 | | | $ | 6,451 | | | $ | 14,598 | | | Weighted average common shares outstanding - basic | 119,301,350 | | | 116,161,251 | | | 118,902,095 | | | 115,588,313 | | | Weighted average common share outstanding - diluted | 125,317,908 | | | 124,570,875 | | | 125,315,681 | | | 124,467,343 | | Earnings per share attributable to Privia Health Group, Inc. common stockholders – basic | $ | 0.03 | | | $ | 0.06 | | | $ | 0.05 | | | $ | 0.13 | | Earnings per share attributable to Privia Health Group, Inc. common stockholders – diluted | $ | 0.03 | | | $ | 0.06 | | | $ | 0.05 | | | $ | 0.12 | |
|
| Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share |
The following outstanding shares of potentially dilutive securities were excluded from computation of diluted loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: | | | | | | | | | | | | | Six Months Ended June 30, | | 2024 | | 2023 | | Potentially dilutive stock options to purchase common stock, RSUs and PSUs | 8,723,227 | | | 6,013,289 | | | Total potentially dilutive shares | 8,723,227 | | | 6,013,289 | |
|